Show simple item record

dc.contributor.authorHernández-Vásquez, A.
dc.contributor.authorChavez-Ecos, F.
dc.contributor.authorBarrenechea-Pulache, A.
dc.contributor.authorComandé, D.
dc.contributor.authorBendezu-Quispe, G.
dc.date.accessioned2025-10-31T18:46:31Z
dc.date.available2025-10-31T18:46:31Z
dc.date.issued2021
dc.identifier.urihttps://hdl.handle.net/20.500.12805/6257
dc.description.abstractBackground: Latin America and the Caribbean (LAC) has presented some of the highest numbers of cases and deaths due to COVID-19 in the world. Even though indigenous communities represent 8% of the total population in this region, the impact of COVID-19 on this historically vulnerable population has only been briefly explored. Thus, this study aimed to estimate the seroprevalence and lethality attributable to SARS-CoV-2 in the indigenous population of LAC. Methods: A systematic review was conducted utilizing multiple databases (registry PROSPERO: CRD42020207862). Studies published in English, Spanish or Portuguese were selected between December 1st, 2019, and April 14th, 2021. The evaluation of the quality of the study was carried out utilizing the Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies. A qualitative synthesis of the data analyzed was conducted following the MOOSE and PRISMA declarations. Results: Fifteen studies met the inclusion criteria. Eleven studies were carried out in a Brazilian population, three in a Mexican population, and one in a Colombian population. Four studies reported data about the seroprevalence of SARS-CoV-2 in indigenous populations of Brazil (range: 4.2-81.65%). Twelve studies reported lethality in indigenous people (eight in Brazil, three in Mexico, and one in Colombia). In Brazil, a lethality of 53.30% was described in a hospital setting and between 1.83% and 4.03% in community studies. In Mexico, the lethality of COVID-19 ranged between 16.5% and 19.9%. Meanwhile, in Colombia, a lethality of 3.41% was reported. Most studies were deemed to be of good quality. Conclusions: Despite COVID-19 affecting indigenous populations of LAC, there is limited evidence of the seroprevalence and lethality of the infection by SARS-CoV-2 in this population. Future investigations should ensure standardized methods that allow comparability among studies and ensure the precision of the results obtained.en_US
dc.description.sponsorshipThis study obtained a grant from the Universidad Privada Norbert Wiener (No. 118-2021-R-UPNW). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
dc.formatapplication/pdf
dc.language.isoeng
dc.publisherPeerJ
dc.relation.ispartofurn:issn:2167-8359
dc.rightshttps://purl.org/coar/access_right/c_abf2
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/
dc.subjectSDG 3en_US
dc.subjectTuberculosis Treatment and Diagnostic Innovationsen_US
dc.subjectHealth and Nutritional Status of Indigenous Populationsen_US
dc.titleSeroprevalence and lethality by SARS-CoV-2 in indigenous populations of Latin America and the Caribbean: A systematic reviewen_US
dc.typehttps://purl.org/coar/resource_type/c_dcae04bc
dc.identifier.doihttps://doi.org/10.7717/peerj.12552
dc.subject.ocdehttps://purl.org/pe-repo/ocde/ford#3.03.05
dc.type.otherReview
dc.identifier.journalPeerJ
dc.type.versionhttps://purl.org/coar/version/c_970fb48d4fbd8a85


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

https://purl.org/coar/access_right/c_abf2
Except where otherwise noted, this item's license is described as https://purl.org/coar/access_right/c_abf2